KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $36.0 million.

  • Pfizer's Other Working Capital Changes fell 9939.92% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 billion, marking a year-over-year increase of 34545.45%. This contributed to the annual value of -$3.4 billion for FY2024, which is 60980.39% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Other Working Capital Changes is $36.0 million, which was down 9939.92% from $5.0 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Other Working Capital Changes registered a high of $8.1 billion during Q4 2022, and its lowest value of -$10.9 billion during Q4 2021.
  • Moreover, its 5-year median value for Other Working Capital Changes was $2.3 billion (2022), whereas its average is $1.1 billion.
  • In the last 5 years, Pfizer's Other Working Capital Changes plummeted by 109500.92% in 2021 and then soared by 65438.36% in 2023.
  • Pfizer's Other Working Capital Changes (Quarter) stood at -$10.9 billion in 2021, then skyrocketed by 174.36% to $8.1 billion in 2022, then plummeted by 223.24% to -$10.0 billion in 2023, then soared by 160.17% to $6.0 billion in 2024, then plummeted by 99.4% to $36.0 million in 2025.
  • Its Other Working Capital Changes stands at $36.0 million for Q3 2025, versus $5.0 billion for Q2 2025 and $1.9 billion for Q1 2025.